
Co-Diagnostics Sets 1-for-25 Reverse Stock Split, Effective Nov. 24
Shares will begin trading split-adjusted on the Nasdaq Capital Market when the market opens Tuesday, Nov. 24, and the ticker stays CODX.
Co-Diagnostics, Inc. · Nasdaq · Surgical & Medical Instruments & Apparatus

Shares will begin trading split-adjusted on the Nasdaq Capital Market when the market opens Tuesday, Nov. 24, and the ticker stays CODX.
No open-market insider buying or selling in the Form 4s filed since July 24, 2026.
Entry into a material definitive agreement · Creation of a direct financial obligation · Unregistered sales of equity securities · Financial statements and exhibits
Material modification of security holders' rights · Amendments to articles or bylaws; fiscal year change · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedCo-Diagnostics announces 1-for-25 reverse stock split effective November 24, 2026, to support Nasdaq $1.00 minimum bid compliance
Departure/appointment of directors or officers · Submission of matters to a vote of security holders · Financial statements and exhibits
AI summary, unreviewedCo-Diagnostics Shareholders Approve Plan Share Increase, Reverse Split Authority of Up to 1-for-750 and Warrant Issuance at Special Meeting
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedCo-Diagnostics Q3 2026 Net Loss Narrows to $1.01 Per Share vs $1.25 Consensus; Revenue Rises to $0.3 Million, Cash Falls to $0.7 Million
Submission of matters to a vote of security holders
Entry into a material definitive agreement · Creation of a direct financial obligation · Unregistered sales of equity securities · Financial statements and exhibits
Entry into a material definitive agreement · Creation of a direct financial obligation · Unregistered sales of equity securities · Financial statements and exhibits